Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 201–300 of 874
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
Mahtani, R. L., Kittaneh, M., Kalinsky, K. M., Mamounas, E. P., Badve, S., Vogel, C. L., Lower, E. E., Schwartzberg, L. S., & Pegram, M. D. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.12.011 · Cited by 49
Self-citationHow I treat HER2-low advanced breast cancer
Schlam, I. M., Tolaney, S. M., & Tarantino, P. (2023) · The Breast · doi:10.1016/j.breast.2023.01.005 · Cited by 48
“[51] Bardia A, Mayer IA, Vahdat LT, et al.”
BackgroundSelf-citationThe Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
Tolaney, S. M., Cardillo, T. M., Chou, C.-C., Dornan, C., & Faris, M. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1525 · Cited by 55
“2 (50–55, 61, 62).”
Self-citationAntibody–drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò, E., Zagami, P., & Curigliano, G. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000656 · Cited by 46
Guo, P., Huang, J., Zhu, B., Huang, A. C., Jiang, L., Fang, J., & Moses, M. A. (2023) · Science Advances · doi:10.1126/sciadv.abq7866 · Cited by 47
“For instance, sacituzumab govitecan, a trophoblast antigen 2 (TROP2) – targeted ADC, was approved for treating refractory TNBC patients with a ~33% response rate and a median progression-free survival of 5.5 months ( 16 ).”
InfluentialHan, C., Perrone, E., Zeybek, B., Bellone, S., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Feinberg, J., Haines, K. E., Karger, M. E. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.018 · Cited by 44
Self-citationPersonalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Azim, H. A., Ghosn, M. G., Oualla, K., & Kassem, L. M. H. (2019) · The Breast Journal · doi:10.1111/tbj.13713 · Cited by 47
Polymeric Nanoparticles for Breast Cancer Therapy: A Comprehensive Review
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac114.1115111171 · Cited by 44
“The different types of breast cancer and TNBC have been depicted in Figure 1 [12-19].”
BackgroundXu, B., Ma, F., Wang, T., Wang, S., Tong, Z., Li, W., Wu, X., Wang, X., Sun, T., Pan, Y., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34424 · Cited by 49
“Triple-negative BC (TNBC) comprises 15-20% of all BCs and approximately 15% of invasive BC cases.(3,4) TNBC is characterized by a lack of expression of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2; is biologically aggressive; and with few targeted agents available, is assoc…”
BackgroundMethodResultInfluentialSystematic characterization of antibody–drug conjugate targets in central nervous system tumors
Coy, S., Lee, J. S., Chan, S. J., Woo, T. Y. C., Jones, J., Alexandrescu, S., Wen, P. Y., Sorger, P. K., Ligon, K. L., & Santagata, S. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad205 · Cited by 45
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., & Wei, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00493-8 · Cited by 50
The treatment landscape of triple-negative breast cancer
Hu, Y., Wang, C., Liang, H., Li, J., & Yang, Q. (2024) · Medical Oncology · doi:10.1007/s12032-024-02456-9 · Cited by 48
“Sacituzumab govitecan-hziy (SG) targeting Trop2 consists of SN-38 connected to the humanized antibody by a pH-sensitive cleavable linker, which has approval by the FDA with the treatment of mTNBC in the IMMU-132-01 trial (NCT01631552) [32].”
The emerging role of RNA N6-methyladenosine methylation in breast cancer
Zheng, F., Du, F., Zhao, J., Wang, X. L., Si, Y., Peng, J., Qian, H., Xu, B., & Yuan, P. (2021) · Biomarker Research · doi:10.1186/s40364-021-00295-8 · Cited by 46
The evolving management of metastatic triple negative breast cancer
Malhotra, M. K., & Emens, L. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.005 · Cited by 42
Touchefeu, Y., Bailly, C., Frampas, É., Eugène, T., Rousseau, C., Bourgeois, M., Bossard, C., Faivre-Chauvet, A., Rauscher, A., Masson, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04989-3 · Cited by 42
“A recently published phase I/II trial investigated sacituzumab govitecan (anti-TROP-2/SN-38 antibody-drug conjugate) in 108 patients with triple-negative breast cancer and showed promising activity and durable responses [20].”
BackgroundSelf-citationPonte, J. F., Lanieri, L., Khera, E., Laleau, R., Ab, O., Espelin, C. W., Kohli, N., Matin, B., Setiady, Y. Y., Miller, M. L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0451 · Cited by 45
Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
Barok, M., Puhka, M., Yazdi, N., & Joensuu, H. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12070 · Cited by 42
“Sacituzumab govitecan is an approved anti-Trop-2 ADC (Bardia et al., 2019) (Table 1), while the clinical development of PF-06664178, another anti-Trop-2 ADC, was stopped (King et al.”
BackgroundImpact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma
Erber, R., Spoerl, S., Mamilos, A., Krupar, R., Hartmann, A., Ruebner, M., Taxis, J., Wittenberg, M., Reichert, T. E., Spanier, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010087 · Cited by 43
Zhao, M., DiPeri, T. P., Raso, M. G., Zheng, X., Rizvi, Y. Q., Evans, K. W., Yang, F., Akçakanat, A., Estecio, M. R., Tripathy, D., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00573-8 · Cited by 44
“In several clinical trials, SG demonstrated durable objective responses in patients with heavily pretreated metastatic TNBC 14,15 , in hormone receptor positive/HER2 negative breast cancer 16 , as well as ef fi cacy signal in several other tumor types including endometrial cancer, prostate cancer…”
BackgroundSun, L., Jia, X., Wang, K., & Li, M. (2024) · The Breast · doi:10.1016/j.breast.2024.103830 · Cited by 49
Schneeweiß, A., Denkert, C., Fasching, P. A., Fremd, C., Gluz, O., Kolberg‐Liedtke, C., Loibl, S., & Lück, H. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0887-0285 · Cited by 45
Xie, W., Zhang, Y., Zhang, S., Wang, F., Zhang, K., Huang, Y., Zhou, Z., Huang, G., & Wang, J. (2019) · PubMed · Cited by 54
A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women
Seung, S. J., Traore, A. N., Pourmirza, B., Fathers, K. E., Coombes, M., & Jerzak, K. J. (2020) · Current Oncology · doi:10.3747/co.27.5769 · Cited by 57
Senkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34525 · Cited by 39
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Telli, M. L., Tolaney, S. M., Shapiro, G. I., Middleton, M. R., Lord, S., Arkenau, H., Tutt, A. N. J., Abramson, V. G., Dean, E. J., Haddad, T. C., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00406-0 · Cited by 44
Self-citationLiu, W., Du, Q., Guo, Z., Ye, X., & Liu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1283247 · Cited by 41
Rousseau, C., Goldenberg, D. M., Colombié, M., Sébille, J.-C., Meingan, P., Ferrer, L., Baumgartner, P., Cerato, E., Masson, D., Campone, M., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236000 · Cited by 40
“Durable objective responses in highly pretreated metastatic triple-negative BC patients, as well as in estrogen receptor–positive, HER2-negative BC, were reported with an antibody–drug conjugate that targets the human trophoblast cell-surface antigen-2, suggesting the advance of a targeted drug conjugate platform for…”
BackgroundSelf-citationWolber, P., Nachtsheim, L., Hoffmann, F. S., Klußmann, J. P., Meyer, M. F., von Eggeling, F., Guntinas‐Lichius, O., Quaas, A., & Arolt, C. (2021) · Head and Neck Pathology · doi:10.1007/s12105-021-01325-5 · Cited by 42
“The potential of Trop-2 as a target for combination therapy using the antibody–drug conjugate sacituzumab govitecan, has already been demonstrated in a number of different tumor entities, such as urothelial carcinoma, squamous cell lung carcinoma and breast cancer [23, 25, 26].”
BackgroundPrat, A., Bardia, A., Curigliano, G., Hammond, M. E. H., Loibl, S., Tolaney, S. M., & Viale, G. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4175 · Cited by 45
Self-citationSacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon
Furlanetto, J., Marmé, F., & Loibl, S. (2022) · Future Oncology · doi:10.2217/fon-2022-0407 · Cited by 42
Li, Y., Zhang, M., Zhang, S., Sun, X., Zhou, C., Li, J., Liu, J., Feng, J., Lu, S., Liu, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114423 · Cited by 44
Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer
Kumari, L., Mishra, L., Patel, P., Sharma, N., Gupta, G. D., & Kurmi, B. D. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2245579 · Cited by 42
“It is believed that the anti-tumour efficacy of sacituzumab govitecan has been enhanced after internalisation of SN-38 in the tumour microenvironment [111, 112].”
BackgroundTang, S., Wynn, C., Le, T., McCandless, M. G., Zhang, Y., Patel, R., Maihle, N. J., & Hillegass, W. B. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10231-5 · Cited by 52
Targeting the tumour cell surface in advanced prostate cancer
Boixareu, C., Taha, T., Venkadakrishnan, V. B., Bono, J. S. D., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01014-w · Cited by 46
“Data in mCRPC are still limited, but the TROP2-directed ADC sacituzumab govitecan was approved by the FDA for use in patients with triple-negative breast cancer 141 , hormone receptor-positive breast cancer 142 and metastatic urothelial cancer 143 .”
Miyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 42
Pavone, G., Motta, L., Martorana, F., Motta, G., & Vigneri, P. G. (2021) · Molecules · doi:10.3390/molecules26237294 · Cited by 49
“Despite some criticisms regarding the conduct of the trials [54], SG efficacy in TNBC patients is consistent across all the phases of its clinical development and eventually leads to regulatory approval in this setting [30,31].”
BackgroundMethodInfluentialReinisch, M., Bruzas, S., Spoenlein, J., Shenoy, S. S., Traut, A., Harrach, H., Chiari, O., Cremer, E., Ataseven, B., Gubelt, L., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231200454 · Cited by 43
Tsujii, S., Serada, S., Fujimoto, M., Uemura, S., Namikawa, T., Nomura, T., Murakami, I., Hanazaki, K., & Naka, T. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0335 · Cited by 37
Emerging treatment strategies for metastatic triple-negative breast cancer
Huppert, L. A., Gümüşay, Ö., & Rugo, H. S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221086916 · Cited by 47
Self-citationSchettini, F., Venturini, S., Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., Placido, P. D., Harbeck, N., Lüftner, D., Denys, H. G., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102468 · Cited by 41
Santi, D. V., Cabel, L., & Bidard, F. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1103 · Cited by 41
“On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab-govitecan (Trodelvy) for adult patients with metastatic triple-negative breast cancer (TNBC) who received at least two prior therapies for metastatic disease (1).”
BackgroundManaging adverse events of sacituzumab govitecan
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2267975 · Cited by 39
“A single arm phase I/II study initially revealed the efficacy of SG in advanced, pretreated TNBC [12].”
BackgroundInfluentialSelf-citationThe role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Shen, M., Liu, S., & Stoyanova, T. I. (2021) · PubMed Central · Cited by 55
Farshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 40
Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
Kaboli, P. J., Shabani, S., Sharma, S., Nasr, M. P., Yamaguchi, H., & Hung, M. (2022) · PubMed · Cited by 62
Petrosyan, V., Dobrolecki, L. E., Thistlethwaite, L. R., Lewis, A. N., Sallas, C., Srinivasan, R. R., Lei, J. T., Kovačević, V., Obradović, P., Ellis, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105799 · Cited by 40
“, chemotherapy).(23) Strikingly, despite these major advances, systemic chemotherapies remain an integral part of the TNBC treatment landscape, and the therapies described above are largely still not biomarker guided despite having well-defined targets.”
BackgroundBiologic therapy for advanced breast cancer: recent advances and future directions
Tarantino, P., Morganti, S., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1752176 · Cited by 42
“5 months and a median OS of 13 months [77].”
BackgroundHsu, M., Hsieh, C.-H., Huang, Y., Chu, S., Chen, C., Lee, W.-J., & Liu, S. (2021) · Cancers · doi:10.3390/cancers13133350 · Cited by 40
Hobbs, E. A., Litton, J. K., & Yap, T. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1952181 · Cited by 39
Antibody-drug Conjugate Targets, Drugs, and Linkers
Teicher, B. A., & Morris, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220224110538 · Cited by 35
Bocci, M., Zana, A., Principi, L., Lucaroni, L., Prati, L., Gilardoni, E., Neri, D., Cazzamalli, S., & Galbiati, A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.014 · Cited by 36
Antibody-drug conjugates in breast cancer: current evidence and future directions
Li, N., Yang, L., Zhao, Z., Du, T., Li, N., Tang, J., & Tang, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00632-9 · Cited by 48
Ouyang, Q., Rodon, J. A., Liang, Y., Wu, X., Li, Q., Song, L., Yan, M., Tong, Z., Liu, Y., Wainberg, Z. A., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01705-2 · Cited by 38
“…has antitumor activity similar to sacituzumab govitecan and dato-DXd, but with a different safety profile and potentially lower incidence of hematologic disorders compared with sacituzumab govitecan [9, 15, 17], which may be attributable to differences in payload and a more stable linker [12].”
InfluentialAntibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Grinda, T., Rassy, E., & Pistilli, B. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01072-5 · Cited by 39
“Sacituzumab govitecan is a first-in-class ADC directed against Trop-2, in which the anti-Trop-2 antibody is coupled via a hydrolysable linker to SN-38, the active metabolite of the topoisomerase I inhibitor, irinotecan [23].”
Evolution of TROP2: Biological insights and clinical applications
Zhang, X., Xiao, H. L., Na, F., Sun, J., Guan, Q., Liu, R., Cai, L., Li, H., & Zhao, M. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117863 · Cited by 41
Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis
Nunnery, S. E., Mayer, I. A., & Balko, J. M. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000494 · Cited by 36
“8).(4) These clinical trial results led to the accelerated FDA approval of this drug for refractory metastatic TNBC in April 2020 becoming the first antibody-drug conjugate approved for TNBC.”
BackgroundResultSelf-citationNano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Dacoba, T. G., Anthiya, S., Berrecoso, G., Fernández‐Mariño, I., Fernández‐Varela, C., Crecente‐Campo, J., Teijeiro‐Osorio, D., Torres, F., & Alonso, M. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009860 · Cited by 34
Saghaeidehkordi, A., Chen, S., Yang, S., & Kaur, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050661 · Cited by 34
“In recent years, several ADCs have been FDA approved to treat hematologic and solid cancers [9,12].”
BackgroundEpaillard, N., Bassil, J., & Pistilli, B. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102597 · Cited by 34
Mito, R., Matsubara, E., Komohara, Y., Shinchi, Y., Sato, K., Yoshii, D., Ohnishi, K., Fujiwara, Y., Tomita, Y., Ikeda, K., et al. (2020) · Pathology International · doi:10.1111/pin.12911 · Cited by 32
An overview of antibody–drug conjugates in oncological practice
Theocharopoulos, C., Lialios, P., Gogas, H. J., & Ziogas, D. C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920962997 · Cited by 32
Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer
Nelly G. Adel, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88626 · Cited by 38
Si, Y., Zhang, Y., Guan, J.-S., Ngo, H. G., Totoro, A., Singh, A. P., Chen, K., Xu, Y., Yang, E. S.-H., Zhou, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9080882 · Cited by 38
Mu, R., Yuan, J., Huang, Y., Meissen, J. K., Mou, S., Liang, M., & Rosenbaum, A. I. (2022) · BioDrugs · doi:10.1007/s40259-022-00518-w · Cited by 38
Li, D., Tao, Z., Wang, B., Wang, L., Cao, J., Hu, X., & Zhang, J. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00462-6 · Cited by 34
Huang, Y.-H., Chu, P., Chen, J., Huang, C., Huang, C.-C., Tsai, Y., Wang, Y.-L., Lien, P., Tseng, L., & Liu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-91588-3 · Cited by 31
An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?
Cherny, N. I. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00636-y · Cited by 34
Peng, W., Jin, X., Xu, X., Yang, Y., Ma, D., Shao, Z., & Jiang, Y. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2143 · Cited by 34
Mechanisms of cancer cell death induction by triptolide: A comprehensive overview
Feng, K., Li, X., Bai, Y., Zhang, D., & Tian, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24335 · Cited by 36
“6 ADCs, which include those that deliberately target CD30, CD22, CD33, Trop2, HER2, and CD79b, have thus far received approval for the management of various malignancies [139].”
BackgroundBianchini, G., Arpino, G., Biganzoli, L., Lonardi, S., Puglisi, F., Santini, D., Lambertini, M., & Pappagallo, G. L. (2022) · Cancers · doi:10.3390/cancers14041022 · Cited by 30
Koster, K., Huober, J., & Joerger, M. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00069 · Cited by 35
“[22] in a phase 1/2 basket-trial including patients with advanced epithelial cancers [22].”
BackgroundTargeted treatment options for the management of metastatic/persistent and recurrent cervical cancer
Mutlu, L., Tymon‐Rosario, J., Harold, J. A., & Menderes, G. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2075348 · Cited by 30
“9 months compared to physicians choice chemotherapy [40,41].”
BackgroundHuang, Y., Del Nagro, C. J., Balic, K., Mylott, W. R., Ismaiel, O. A., Ma, E., Faria, M., Wheeler, A. M., Yuan, M., Waldron, M. P., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01187 · Cited by 29
Breast Cancer: Extracellular Matrix and Microbiome Interactions
Herrera‐Quintana, L., Vázquez‐Lorente, H., & Plaza‐Díaz, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137226 · Cited by 36
“…factors, minimally invasive procedures [9] such as laparoscopic and robotic surgery, improved screening and early detection [10], cost-effective [11] drug development, combination therapies [12] using combinations of drugs that work synergistically, and telemedicine and remote monitoring [13].”
Villacampa, G. J., Morgado, P. C., Carità, L., Navarro, V., Pascual, T., & Dienstmann, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102847 · Cited by 35
Development of Novel Antibody–Camptothecin Conjugates
Lyski, R. D., Bou, L. B., Lau, U. Y., Meyer, D. W., Cochran, J. H., Okeley, N. M., Emmerton, K. K., Zapata, F., Simmons, J. K., Trueblood, E. S., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0526 · Cited by 29
Research advances and new challenges in overcoming triple-negative breast cancer
Zong, Y., & Pegram, M. D. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.04 · Cited by 45
“The FDA-registrational phase 1/2 single-arm IMMU-132–01 clinical trial (NCT01631552) enrolled 108 TNBC patients who have received at least two prior lines of therapy[76].”
BackgroundMethodVranić, S., & Gatalica, Z. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.6100 · Cited by 39
“The FDA decision was based on the efficacy of SG that had been demonstrated in the IMMU-132-01 (NCT 01631552) clinical trial [35].”
BackgroundMethodInfluentialWu, T.-N., Chen, H.-M., & Shyur, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413571 · Cited by 31
“refractory metastatic TNBC patients (phase I/II, n = 108) 10 mg/kg, intravenously on days 1 and 8 of each 21-day cycle [83]”
BackgroundSankaranarayanan, R. A., Peil, J., Vogg, A. T. J., Bolm, C., Terhorst, S., Claßen, A., Bauwens, M., Maurer, J., Mottaghy, F. M., & Morgenroth, A. (2022) · Cancers · doi:10.3390/cancers14010230 · Cited by 30
“Additionally, the anti-Trop2 antibodydrug conjugate, sacituzumab govitecan-hziy, was approved for patients with refractory metastatic TNBC [4,5].”
BackgroundQin, J., Sun, X., Ma, Y., Cheng, Y., Ma, Q., Jing, W., Qu, S., & Liu, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116594 · Cited by 32
Guerra, E., Relli, V., Ceci, M., Tripaldi, R., Simeone, P., Aloisi, A. L., Pantalone, L., Sorda, R. L., Lattanzio, R., Sacchetti, A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02220-1 · Cited by 32
“Challenging R-GECO-expressing Trop2–positive cells with RS-7—an anti-Trop-2 mAb developed into the antibody-SN-38 drug conjugate Sacituzumab govitecan-hziy (Trodelvy) [11, 12]—did not induce any increase of Ca levels (Supplementary Fig.”
BackgroundLiu, C., Zhao, Z., Gao, R., Zhang, X., Sun, Y.-L., Wu, J., Liu, J., & Chen, C. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00295 · Cited by 30
ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2
Huebner, K., Erlenbach‐Wuensch, K., Procházka, J., Sheraj, I., Hampel, C., Mrázková, B., Michalčíková, T., Turečková, J., Iatsiuk, V., Weissmann, A., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04445-5 · Cited by 31
“Considering several ongoing clinical trials [37] and the recently FDA-approved drug sacituzumab govitecan-hziy, which combines a TROP2-directed antibody and a topoisomerase inhibitor [38, 39], TROP2 holds promise as a marker for tumor aggressiveness in CRC patients.”
BackgroundAtezolizumab in the treatment of metastatic triple-negative breast cancer
Pérez-García, J. M., Soberino, J., Racca, F., Gión, M., Stradella, A., & Cortés, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1769063 · Cited by 31
Sayama, Y., Kaneko, M. K., & Kato, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11731 · Cited by 28
“The expression of TROP2 has been reported in more than 85% of all tumors; as such, TROP2 may be a useful marker for cancer diagnosis and immunotherapy (2,14,15).”
Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer
Cruz-Collazo, A., Ruiz-Calderon, J. F., Picon, H. M., Borrero-García, L. D., Lopez, I., Castillo-Pichardo, L., Maldonado, M. D. M., Duconge-Soler, J., Medina, J. I., Bayro, M. J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0348 · Cited by 34
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
Schlam, I. M., & Gatti-Mays, M. E. (2022) · The Oncologist · doi:10.1093/oncolo/oyac064 · Cited by 38
Li, G., Suzuki, H., Ohishi, T., Asano, T., Tanaka, T., Yanaka, M., Nakamura, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5221 · Cited by 30
“Vicinium was approved by the FdA as fast track designation and evaluated in the single‑arm Phase 3 VISTA study (NcT02449239) for the patients with high‑grade NMIBc previously treated with BcG.”
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
Subhan, M. A., & Torchilin, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041242 · Cited by 30
“The outcome of the study with metastatic TNBC patients was published in 2019 [86].”
BackgroundSaini, S., Gulati, N., Awasthi, R., Arora, V., Singh, S. K., Kumar, S., Gupta, G., Dua, K., Pahwa, R., & Dureja, H. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230731094258 · Cited by 29
Targeting Trop2 in solid tumors: a look into structures and novel epitopes
Liu, X., Li, J., Deng, J., Zhao, J., Zhao, G., Zhang, T., Jiang, H., Liang, B., Xing, D., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332489 · Cited by 31
Shin, C., Kim, S. S., & Jo, Y. H. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.005 · Cited by 27
“Sacituzumab govitecan-hziy, or TRODELVY, is an ADC agent composed of anti-triophoblast cell-surface antigen 2 (Trop-2), hRS7 IgG1k antibody conjugated to topoisomerase I inhibitor (SN-38), an activemetabolite of irinotecan,with a cleavableCL2A linker.(126) InApril 22, 2020, it was approved by the FDA to be administere…”
BackgroundChen, J., Han, M., Liu, A., & Shi, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734594 · Cited by 33
“These approvals were based on the results of a phase I/II trial (NCT01631552) (9) and a confirmatory phase III trial (NCT02574455) (10).”
BackgroundTROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer
Cortesi, M., Zanoni, M., Maltoni, R., Ravaioli, S., Tumedei, M. M., Pirini, F., & Bravaccini, S. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2113513 · Cited by 28
“In this study, Trop2 expression was determined by IHC and the highest protein levels were observed in TNBCs, followed by HER2+ and finally in ER+ tumors.”
BackgroundInfluentialRecent advancement in breast cancer treatment using CAR T cell therapy:- A review
Dey, A., Ghosh, S., Jha, S., Hazra, S., Srivastava, N., Chakraborty, U., & Roy, A. G. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100090 · Cited by 30
Antibody-Drug Conjugates in Triple Negative Breast Cancer
Keskinkılıç, M., & Sacks, R. L. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.01.008 · Cited by 34
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025) · Cancers · doi:10.3390/cancers17030353 · Cited by 35
“It became the first anti-TROP-2 ADC to be approved for metastatic triple-negative breast cancer based on the single-arm clinical trial results of IMMU-132-01, with an ORR of 33.3% and a median DOR of 77.7 months [191].”
InfluentialAnaemia in cancer patients: Advances and challenges in the era of precision oncology
Miglietta, F., Pirozzi, M., Bottosso, M., Pisani, C., Franco, P., Guarneri, V., & Gennari, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104788 · Cited by 28
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Cipriano, É., & Mesquita, A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234211002491 · Cited by 31
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.